Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension [PDF]
Lancet Neurology, The, 2018 Background: Although several disease-modifying treatments are available for relapsing multiple sclerosis, treatment effects have been more modest in progressive multiple sclerosis and have been observed particularly in actively relapsing subgroups or ...
Douglas L Arnold +2 more
exaly +6 more sources
Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation. [PDF]
PLoS ONE, 2016 The anti-CD49d monoclonal antibody natalizumab is currently an effective therapy against the relapsing-remitting form of multiple sclerosis (RRMS). Natalizumab therapeutic efficacy is limited by the reactivation of the John Cunningham polyomavirus (JCV ...
Marco Iannetta +15 more
doaj +10 more sources
Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlook [PDF]
Therapeutic Advances in Neurological DisordersTwenty years on from its initial approval as the first monoclonal antibody for the treatment of multiple sclerosis (MS), natalizumab remains a valuable high-efficacy treatment option for people with relapsing-remitting MS, with robust real-world evidence
Luisa Klotz +10 more
doaj +2 more sources
Drugs of Today, 2006 Medical therapeutics has entered a new and exciting era with the development of biological agents that target specific sites. In the studies performed to date, natalizumab, a humanized monoclonal antibody to alpha4 integrin, when administered intravenously at monthly intervals, appeared to be highly beneficial with respect to decreasing both relapse ...
europepmc +3 more sources
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report [PDF]
Journal of Medical Case Reports, 2009 Introduction Natalizumab is a new treatment for relapsing-remitting multiple sclerosis. Because of limited experience of this treatment, medical professionals must be alert to possible side effects.
Gatzonis Stylianos, Siatouni Anna
doaj +3 more sources
In vitro morphological profiling of T cells predicts clinical response to natalizumab therapy in patients with multiple sclerosis [PDF]
Nature CommunicationsDespite the efficacy of natalizumab, which targets the integrin VLA-4, in treating multiple sclerosis (MS), approximately 35% patients with MS present evidence of disease activity two years after treatment initiation.
Beatriz Chaves +14 more
doaj +2 more sources
Real-World Effectiveness of Natalizumab in Korean Patients With Multiple Sclerosis
Frontiers in Neurology, 2021 Background and Purpose: Natalizumab is a highly efficacious disease-modifying therapy for relapsing-remitting multiple sclerosis (MS). Data on the efficacy and safety profile of natalizumab in Asian patients with MS are limited.
Ki Hoon Kim +4 more
doaj +1 more source
American Journal of Neuroradiology, 2010 Natalizumab is a humanized IgG4κ monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanism of action and clinical role of this agent.
D T, Selewski +4 more
openaire +2 more sources
Arquivos de Neuro-Psiquiatria, 2021 Background: The real-world effectiveness of natalizumab in people with relapsing multiple sclerosis (PwRMS) in Argentina and Chile has not been reported.
Maria Celica Ysrraelit +7 more
doaj +1 more source
Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis. [PDF]
PLoS ONE, 2012 Natalizumab is an effective monoclonal antibody therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS) and interferes with immune cell migration into the central nervous system by blocking the α(4) subunit of very-late activation ...
Andrea Harrer +11 more
doaj +1 more source